Cancer Pain: Comparison of Oral Morphine and Transdermal Fentanyl Treatment
DOI:
https://doi.org/10.5457/ams.v40i1.176Keywords:
cancer pain, morphine, transdermal fentanyl.Abstract
Aim: The aim of the research is to compare the efficiency of equianalgesic dosages of transdermal fentanyl and oral morphine in severe cancer pain treatment in patients with or without bone metastasis. Patients and methods. 80 patients who were treated with transdermal fentanyl due to severe cancer pain (from 7 to 10 on the NRS scale) and oral morphine were examined by a prospective research conducted at the Palliative care centre (hospice) of University Clinical Centre Tuzla. In the statistical analysis T-test, Mann-Whitney test, Wilcoxon test and χ2 tests were used. The difference between samples was considered important if p < 0.05. Results. The Karnofsky score for all 80 patients upon admission was 47.13 ± 11.05 and 51.25 ± 11.73 upon dismissal (p = 0.0005). In patients with bone metastasis compared to those without bone metastasis, neurophatic pain is dominant (p = 0,02). Mean pain intensity in all patients on the first day of treatment was 9.00 (from 7.00 to 10.00) which is statistically significantly more (p < 0.0001) compared to pain intensity on the tenth day of treatment. Higher pain intensity was noted in patients with bone metastasis in all 10 days or research. Conclusion. During the first three days of study pain intensity was lower in patients from the control group, and on the fourth day lower pain intensity was noted in patients who were treated with transdermal fentanyl.
Downloads
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
